Follow
Mark E. Robson
Title
Cited by
Cited by
Year
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
M Robson, SA Im, E Senkus, B Xu, SM Domchek, N Masuda, S Delaloge, ...
New England Journal of Medicine 377 (6), 523-533, 2017
29102017
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
A Zehir, R Benayed, RH Shah, A Syed, S Middha, HR Kim, P Srinivasan, ...
Nature medicine 23 (6), 703-713, 2017
28922017
Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
A Tutt, M Robson, JE Garber, SM Domchek, MW Audeh, JN Weitzel, ...
The Lancet 376 (9737), 235-244, 2010
21522010
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation
ND Kauff, JM Satagopan, ME Robson, L Scheuer, M Hensley, CA Hudis, ...
New England Journal of Medicine 346 (21), 1609-1615, 2002
16542002
Inherited DNA-repair gene mutations in men with metastatic prostate cancer
CC Pritchard, J Mateo, MF Walsh, N De Sarkar, W Abida, H Beltran, ...
New England Journal of Medicine 375 (5), 443-453, 2016
15442016
Gene-panel sequencing and the prediction of breast-cancer risk
DF Easton, PDP Pharoah, AC Antoniou, M Tischkowitz, SV Tavtigian, ...
New England Journal of Medicine 372 (23), 2243-2257, 2015
10092015
Polygenic risk scores for prediction of breast cancer and breast cancer subtypes
N Mavaddat, K Michailidou, J Dennis, M Lush, L Fachal, A Lee, JP Tyrer, ...
The American Journal of Human Genetics 104 (1), 21-34, 2019
8862019
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
F Mosele, J Remon, J Mateo, CB Westphalen, F Barlesi, MP Lolkema, ...
Annals of Oncology 31 (11), 1491-1505, 2020
8432020
A note on competing risks in survival data analysis
JM Satagopan, L Ben-Porat, M Berwick, M Robson, D Kutler, ...
British journal of cancer 91 (7), 1229-1235, 2004
7892004
The genomic landscape of endocrine-resistant advanced breast cancers
P Razavi, MT Chang, G Xu, C Bandlamudi, DS Ross, N Vasan, Y Cai, ...
Cancer cell 34 (3), 427-438. e6, 2018
7822018
Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)
N Mavaddat, D Barrowdale, IL Andrulis, SM Domchek, D Eccles, ...
Cancer Epidemiology, Biomarkers & Prevention 21 (1), 134-147, 2012
7522012
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1-and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study
ND Kauff, SM Domchek, TM Friebel, ME Robson, J Lee, JE Garber, ...
Journal of clinical oncology 26 (8), 1331, 2008
7042008
Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study
SA Narod, JS Brunet, P Ghadirian, M Robson, K Heimdal, SL Neuhausen, ...
The Lancet 356 (9245), 1876-1881, 2000
6752000
Genetic/familial high-risk assessment: breast and ovarian
MB Daly, JE Axilbund, S Buys, B Crawford, CD Farrell, S Friedman, ...
Journal of the National Comprehensive Cancer Network 8 (5), 562-594, 2010
668*2010
Prediction of breast cancer risk based on profiling with common genetic variants
N Mavaddat, PDP Pharoah, K Michailidou, J Tyrer, MN Brook, MK Bolla, ...
Journal of the National Cancer Institute 107 (5), djv036, 2015
6652015
Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes
CC Coombs, A Zehir, SM Devlin, A Kishtagari, A Syed, P Jonsson, ...
Cell stem cell 21 (3), 374-382. e4, 2017
6552017
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2 …
ME Robson, N Tung, P Conte, SA Im, E Senkus, B Xu, N Masuda, ...
Annals of Oncology 30 (4), 558-566, 2019
6452019
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer
SE Bojesen, KA Pooley, SE Johnatty, J Beesley, K Michailidou, JP Tyrer, ...
Nature genetics 45 (4), 371-384, 2013
6422013
Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk.
TS Frank, SA Manley, OI Olopade, S Cummings, JE Garber, B Bernhardt, ...
Journal of Clinical Oncology 16 (7), 2417-2425, 1998
5901998
American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility
ME Robson, AR Bradbury, B Arun, SM Domchek, JM Ford, HL Hampel, ...
Journal of Clinical Oncology 33 (31), 3660-3667, 2015
5852015
The system can't perform the operation now. Try again later.
Articles 1–20